title: [Influence of transplantation and some clinical factors on prognosis of patients with diffuse large B-cell lymphoma].
abstract: This study was aimed to analyze the survival status of patients with diffuse large B-cell lymphoma (DLBCL) and to investigate the influence of autologous hematopoietic stem cell transplantation (auto-HSCT), different pathological types, International Prognosis Idex (IPI) on prognosis. One hundred and sixteen cases of DLBCL were analyzed retrospectively. The treatment efficacy of R-CHOP alone and R-CHOP combined with auto-HSCT as well as the influence of different immunopathologic types, IPI, hypersensitive C-reactive protein (HSCRP), α-hydroxybutyric acid deaminase (HBDH) on the prognosis of DLBCL patients including overall survival (OS) rate, progression-free survival (PFS) rate were analyzed. The results indicated that the 5-year OS for all patients was 72.4%. in which 30 patients with Ann Arbor staging III-IV received auto-HSCT plus R-CHOP. The prognosis of the 30 patients was better than that of 86 cases received R-CHOP chemotherapy alone (5-year OS was 82.5% vs 69.0%, 5-year PFS was 77.1% vs 68.3%) (P < 0.05). The prognosis of patients in germinal center B-cell-like group (GCB group) was better than that of patients in activated B-cell-like group (ABC group). Some clinical features were associated with poor prognosis including OS and PFS, such as age, B symptoms, IPI scores, the level of LDH, HSCRP and HBDH (P < 0.05) in which the level of LDH, age ≥ 60 years and B symptoms were independent prognostic factors in DLBCL patients (P < 0.05). It is concluded that auto-HSCT combined with R-CHOP can improve the long-term survival of DLBCL patients. The prognosis of patients in GCB group is better than that of patients in the ABC group. The clinical features such as age, B symptoms, IPI scores and LDH are associated with prognosis.
authors.affiliation: Jiangsu Institute of Hematology, Soochow University First Affiliated Hospital, Jiangsu Province, China.
authors.forename: Shi-Xiang
authors.initials: SX
authors.lastname: Zhao
authors.forename: Yue
authors.initials: Y
authors.lastname: Han
authors.forename: Qian
authors.initials: Q
authors.lastname: Zhu
authors.forename: Qian
authors.initials: Q
authors.lastname: Wang
authors.forename: Wen-Juan
authors.initials: WJ
authors.lastname: Zhang
authors.forename: Xiao-Chen
authors.initials: XC
authors.lastname: Chen
authors.forename: Ai-Ning
authors.initials: AN
authors.lastname: Sun
authors.forename: Zheng-Ming
authors.initials: ZM
authors.lastname: Jin
authors.forename: Hui-Ying
authors.initials: HY
authors.lastname: Qiu
authors.forename: Xiao-Wen
authors.initials: XW
authors.lastname: Tang
authors.forename: Zhen-Zhen
authors.initials: ZZ
authors.lastname: Fu
authors.forename: Guang-Sheng
authors.initials: GS
authors.lastname: He
authors.forename: Miao
authors.initials: M
authors.lastname: Miao
authors.forename: Xiao
authors.initials: X
authors.lastname: Ma
authors.forename: De-Pei
authors.initials: DP
authors.lastname: Wu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols; D003520:Cyclophosphamide; D004317:Doxorubicin; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011241:Prednisone; D011379:Prognosis; D012189:Retrospective Studies; D000069283:Rituximab; D014750:Vincristine; D055815:Young Adult
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone